DK2825181T3 - Porøse carbonpartikler til anvendelse i behandling eller forebyggelse af leversygdom - Google Patents

Porøse carbonpartikler til anvendelse i behandling eller forebyggelse af leversygdom Download PDF

Info

Publication number
DK2825181T3
DK2825181T3 DK13711116.7T DK13711116T DK2825181T3 DK 2825181 T3 DK2825181 T3 DK 2825181T3 DK 13711116 T DK13711116 T DK 13711116T DK 2825181 T3 DK2825181 T3 DK 2825181T3
Authority
DK
Denmark
Prior art keywords
prevention
treatment
carbon particles
liver disease
porous carbon
Prior art date
Application number
DK13711116.7T
Other languages
English (en)
Inventor
Carol Angela Howell
Sergey Victorovich Mikhalovsky
Susan Rachel Sandeman
Rajiv Jalan
Jane Macnaughtan
Original Assignee
Ucl Business Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ucl Business Ltd filed Critical Ucl Business Ltd
Application granted granted Critical
Publication of DK2825181T3 publication Critical patent/DK2825181T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/44Elemental carbon, e.g. charcoal, carbon black
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1611Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682Processes
    • A61K9/1688Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • A61P39/02Antidotes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C01INORGANIC CHEMISTRY
    • C01BNON-METALLIC ELEMENTS; COMPOUNDS THEREOF; METALLOIDS OR COMPOUNDS THEREOF NOT COVERED BY SUBCLASS C01C
    • C01B32/00Carbon; Compounds thereof
    • C01B32/15Nano-sized carbon materials
    • CCHEMISTRY; METALLURGY
    • C01INORGANIC CHEMISTRY
    • C01PINDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
    • C01P2004/00Particle morphology
    • C01P2004/60Particles characterised by their size
    • C01P2004/64Nanometer sized, i.e. from 1-100 nanometer
    • CCHEMISTRY; METALLURGY
    • C01INORGANIC CHEMISTRY
    • C01PINDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
    • C01P2006/00Physical properties of inorganic compounds
    • C01P2006/16Pore diameter
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10TTECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00Stock material or miscellaneous articles
    • Y10T428/29Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982Particulate matter [e.g., sphere, flake, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Biotechnology (AREA)
  • Materials Engineering (AREA)
  • Nanotechnology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Carbon And Carbon Compounds (AREA)
DK13711116.7T 2012-03-16 2013-03-15 Porøse carbonpartikler til anvendelse i behandling eller forebyggelse af leversygdom DK2825181T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1204696.7A GB201204696D0 (en) 2012-03-16 2012-03-16 Therapy
PCT/GB2013/050673 WO2013136094A1 (en) 2012-03-16 2013-03-15 Porous carbon particles for use in the treatment or prevention of liver disease

Publications (1)

Publication Number Publication Date
DK2825181T3 true DK2825181T3 (da) 2020-04-14

Family

ID=46052080

Family Applications (1)

Application Number Title Priority Date Filing Date
DK13711116.7T DK2825181T3 (da) 2012-03-16 2013-03-15 Porøse carbonpartikler til anvendelse i behandling eller forebyggelse af leversygdom

Country Status (16)

Country Link
US (1) US9844568B2 (da)
EP (2) EP3650031A1 (da)
JP (2) JP6293680B2 (da)
KR (2) KR102142504B1 (da)
CN (1) CN104363916B (da)
AU (1) AU2013234099B2 (da)
BR (1) BR112014022810B1 (da)
DK (1) DK2825181T3 (da)
EA (1) EA038965B1 (da)
GB (1) GB201204696D0 (da)
IN (1) IN2014DN07637A (da)
MY (1) MY169093A (da)
NZ (1) NZ631429A (da)
SG (1) SG11201405771QA (da)
WO (1) WO2013136094A1 (da)
ZA (1) ZA201406989B (da)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201204696D0 (en) * 2012-03-16 2012-05-02 Ucl Business Plc Therapy
WO2015161200A1 (en) * 2014-04-17 2015-10-22 ImMutriX Therapeutics, Inc. Therapeutic detoxification compositions and methods of making and using same
TWI607765B (zh) * 2014-08-27 2017-12-11 Kureha Corp Adsorbents for oral administration, and nephropathy therapeutic agents and liver disease therapeutic agents
CA3191747A1 (en) 2017-03-31 2018-10-04 Axial Therapeutics, Inc. Gut-selective sequestering agents for the treatment and prevention of autism and related disorders
EP3476818A1 (en) 2017-10-27 2019-05-01 Heraeus Battery Technology GmbH A process for the preparation of a porous carbon material using an improved carbon source
EP3476817A1 (en) 2017-10-27 2019-05-01 Heraeus Battery Technology GmbH A process for the preparation of a porous carbon material using an improved amphiphilic species
WO2019131209A1 (ja) * 2017-12-27 2019-07-04 株式会社クラレ 活性炭およびその製法
WO2020085282A1 (ja) * 2018-10-24 2020-04-30 フタムラ化学株式会社 フェノール樹脂の製造方法
JP7228498B2 (ja) * 2018-10-24 2023-02-24 フタムラ化学株式会社 フェノール樹脂の製造方法
JP7338993B2 (ja) * 2019-03-06 2023-09-05 株式会社クラレ 多孔質炭素および多孔質炭素の製造方法
CN113874320B (zh) * 2019-04-16 2023-12-19 二村化学株式会社 活性炭吸附剂的制造方法
JP7061640B2 (ja) * 2019-04-16 2022-04-28 フタムラ化学株式会社 活性炭吸着剤の製造方法

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5332637B2 (da) 1973-05-09 1978-09-09
JPS51151693A (en) 1975-06-23 1976-12-27 Eisai Co Ltd Coated bead-like activated carbon for blood purification
JPS5673542A (en) 1979-11-22 1981-06-18 Kureha Chem Ind Co Ltd Adsorbent
JPS5731864A (en) 1980-08-04 1982-02-20 Teijin Ltd Oral activated carbon microcapsule
RU2177319C2 (ru) * 1999-03-30 2001-12-27 Российская медицинская академия последипломного образования МЗ РФ Способ лечения гиперэндотоксинемии
GB0019417D0 (en) 2000-08-09 2000-09-27 Mat & Separations Tech Int Ltd Mesoporous carbons
JP3522708B2 (ja) 2001-04-11 2004-04-26 呉羽化学工業株式会社 経口投与用吸着剤
JP4311923B2 (ja) 2002-10-07 2009-08-12 株式会社クレハ 経口投与用肝疾患治療又は予防剤
DK1407772T3 (da) 2002-10-09 2006-12-11 Kureha Corp Farmaceutisk præparat, der omfatter poröst sfærisk carbonholdigt stof, og dets anvendelse til behandling af nyre- og leversygdomme
US7651974B2 (en) 2002-11-01 2010-01-26 Kureha Chemical Industry Co., Ltd. Adsorbent for oral administration
JP3835698B2 (ja) 2002-11-01 2006-10-18 株式会社クレハ 経口投与用吸着剤、並びに腎疾患治療又は予防剤、及び肝疾患治療又は予防剤
JP2005089306A (ja) 2003-09-12 2005-04-07 Ajinomoto Co Inc 炎症性腸疾患治療用の経直腸投与製剤
JP4382629B2 (ja) 2003-10-22 2009-12-16 株式会社クレハ 経口投与用吸着剤、並びに腎疾患治療又は予防剤、及び肝疾患治療又は予防剤
KR101135260B1 (ko) 2003-10-22 2012-04-12 가부시키가이샤 쿠레하 경구투여용 흡착제, 신질환 치료 또는 예방제 및 간질환치료 또는 예방제
TWI370013B (en) * 2004-04-02 2012-08-11 Kureha Corp Adsorbent for oral administration, and agent for treating or preventing renal or liver disease
TWI370012B (en) 2004-04-02 2012-08-11 Kureha Corp Adsorbent for oral administration, and agent for treating or preventing renal or liver disease
JP2007045775A (ja) 2005-08-11 2007-02-22 Japan Organo Co Ltd 含水活性炭及びその製造方法
DE102005062160A1 (de) 2005-12-19 2007-06-21 BLüCHER GMBH Aktivkohle für die medizinische Verwendung
US8048413B2 (en) 2006-05-17 2011-11-01 Helene Huguet Site-specific intestinal delivery of adsorbents, alone or in combination with degrading molecules
EP2054342B1 (en) 2006-10-09 2019-07-31 British American Tobacco (Investments) Limited Making discrete solid particles of polymeric material
WO2008043982A2 (en) 2006-10-09 2008-04-17 British American Tobacco (Investments) Limited Carbonising and/or activating carbonaceous material
WO2010138519A2 (en) 2009-05-27 2010-12-02 Ocera Therapeutics, Inc. Use of adsorbent carbon microspheres for the treatment of pruritus
GB0921528D0 (en) * 2009-12-09 2010-01-27 Mast Carbon Internat Ltd Carbon and its use in blood cleansing applications
KR101820374B1 (ko) 2010-02-23 2018-01-19 다 볼떼라 장 내 흡착제의 경구 전달을 위한 제형
JP5984352B2 (ja) * 2010-10-12 2016-09-06 フタムラ化学株式会社 経口投与用医薬用吸着剤の製造方法
GB201204696D0 (en) * 2012-03-16 2012-05-02 Ucl Business Plc Therapy

Also Published As

Publication number Publication date
MY169093A (en) 2019-02-18
SG11201405771QA (en) 2014-10-30
EP2825181B1 (en) 2020-01-08
BR112014022810B1 (pt) 2021-04-13
KR20150002675A (ko) 2015-01-07
JP2018111699A (ja) 2018-07-19
WO2013136094A1 (en) 2013-09-19
KR102142504B1 (ko) 2020-08-07
KR102441934B1 (ko) 2022-09-08
NZ631429A (en) 2016-09-30
AU2013234099B2 (en) 2017-03-30
EP3650031A1 (en) 2020-05-13
IN2014DN07637A (da) 2015-05-15
AU2013234099A1 (en) 2014-10-02
ZA201406989B (en) 2015-12-23
JP6647570B2 (ja) 2020-02-14
EP2825181A1 (en) 2015-01-21
JP2015516373A (ja) 2015-06-11
JP6293680B2 (ja) 2018-03-14
US9844568B2 (en) 2017-12-19
KR20200096991A (ko) 2020-08-14
US20150064256A1 (en) 2015-03-05
EA038965B1 (ru) 2021-11-16
CN104363916B (zh) 2018-09-25
CN104363916A (zh) 2015-02-18
EA201491690A1 (ru) 2015-02-27
GB201204696D0 (en) 2012-05-02

Similar Documents

Publication Publication Date Title
DK2825181T3 (da) Porøse carbonpartikler til anvendelse i behandling eller forebyggelse af leversygdom
DK2981274T3 (da) Probiotiske stammer til anvendelse ved behandling eller forebyggelse af osteoporose
CO7061071A2 (es) Procesos para la preparación de (s)-1-(3-etoxi-4-metoxifenil)-2-metansulfoniletilamina
DK3329909T3 (da) Fenfluramin til anvendelse i behandling af dravet syndrom
DK2938740T3 (da) Kimære fgf19-peptider til anvendelse til behandling af galdesyrelidelser
DK2819602T3 (da) Kateter til behandling af atrieflagren med enkelt-virkende dobbelt afbøjningsmekanisme
DK2818481T3 (da) Farmaceutisk sammensætning til behandling og/eller forebyggelse af cancer
DK2919796T3 (da) Brug af akkermansia til behandling af stofskiftesygdomme
DK2898061T3 (da) Probiotiske sammensætninger til behandlingen af fedme og fedme-relaterede tilstande
DK2836200T3 (da) Termoreversible hydrogelpræparater til anvendelse i behandlingen af lidelser i urothelium
BR112014010175A2 (pt) unidades de filtro, componentes e recursos destas e métodos de uso e construção
DK2895156T3 (da) Fremgangsmåde til fremstilling af terapeutiske nanopartikler
DK2815769T3 (da) Fam19a5 til anvendelse i diagnosticering og behandling af skader på centralnervesystemet
DK2841097T3 (da) Sammensætninger og fremgangsmåder til behandling og forebyggelse af porcint reproduktions- og respirationssyndrom
DK3082831T3 (da) Sammensætning på basis af methyl-cyclodextriner til behandling og/eller forebyggelse af sygdomme ved forøgelse af koncentrationen af hdl-kolesterol
DK3040336T3 (da) Forbindelser til brug i behandling af TYK2 Kinase-medierede tilstande
BR112013024401A2 (pt) métodos e composições para o tratamento do transtorno do déficit de atenção
DK2838549T3 (da) Farmaceutisk præparat til forebyggelse eller behandling af ikke-alkoholisk fedtleversygdom
DK3730136T3 (da) Anvendelse af ferricitrat til behandlingen af patienter med kronisk nyresygdom
DK3054976T3 (da) Anvendelse af semaphorin-4d-bindende molekyler til behandling af aterosklerose
DK2854850T3 (da) Sammensætninger til behandling eller forebyggelse af strålingssygdom og gi-syndrom
DK2945642T3 (da) Faktor 1 protein til anvendelse i behandling eller forebyggelse af sygdomme
DK3581199T3 (da) Fremgangsmåder til behandling eller reduktion af ødematøs fibrosklerotisk pannikulitis
DK2917231T3 (da) Lipopeptider til anvendelse ved behandling af leversygdomme og hjerte-kar-sygdomme
DK3366307T3 (da) Sammensætninger og fremgangsmåder til inhibering af masp-1 og/eller masp-3 til behandling af paroxystisk nokturn hæmoglobinuri